Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + trastuzumab + paclitaxel + cisplatin as preoperative therapy for HER2-positive breast cancer
ChiCTR1800020449Phase 4Not yet recruiting
- Sponsor
- Breast Center of Jiangxi Tumor Hospital
- Start
- Mar 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pyrotinib, trastuzumab, paclitaxel and cisplatin in breast cancer, sponsored by Breast Center of Jiangxi Tumor Hospital. Primary endpoint: total pathological complete response. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1800020449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020449.